NAMS
SHORT CANDIDATEMeanRevComposite
20.90
Technical
7.90
Fundamental
25.20
Rank
—
Price
23.20
Hurst
0.14
As of
Oct 5, 2026
Daily
NewAmsterdam Pharma Company N.V.
HealthcareBiotechnologyNewAmsterdam Pharma is a biopharmaceutical company developing drug candidates to treat patients with conditions related to heart and metabolic health. Its primary program, Obicetrapib, is an oral CETP inhibitor being tested in clinical trials both alone and combined with ezetimibe to reduce LDL cholesterol levels and address cardiovascular disease, while the same compound is also under investigation in early-stage trials for Alzheimer's disease. The company is based in the Netherlands.
Market cap
$2.6B
P/E (trailing)
—
P/E (forward)
-14.56
PEG ratio
—
Dividend yield
0.00%
Beta
0.10
52w range
21.02 – 42.21
Return on equity
-36.81%
Profit margin
0.00%
Revenue growth
-80.70%
Earnings growth
—
Price history
1Y: 22.30 (-31.3%) · range 21.16–41.45
Cycle position
22/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 60 · MODERATE · exit proximity 0
Conviction
40/ 100 · maturity 57%
VScore.2833
Buildup.2434
EMA entry setup.3060
Fundamentals.1825
Volume profile
POC
22.50
Price vs POC
+3.1%
Overhead supply
84%
Runway
+18.9%
Value area 21.02–32.88 · 84% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| breakdown-signal | 1.000 | Oct 5, 2026 |
Pattern & cluster
Pattern
NEUTRAL
Cluster
NEUTRALForward returns
Not yet labeled — the study prices these as positions mature.